Studies on the Preparation and Evaluation of Chitosan Nanoparticles containing Cytarabine
DOI:
https://doi.org/10.37285/ijpsn.2010.3.2.9Abstract
The activity of cytarabine was decreased by its rapid deamination to the biologically inactive metabolite uracil arabinoside. This rapid deamination is the reason for the ongoing research for effective formulation of cytarabine that can not be deaminated and exhibit better pharmacokinetic parameters. Protection of cytarabine from fast degradation and elimination was investigated by encapsulating the drug into chitosan nanoparticles. Cytarabine loaded nanoparticles prepared by ionotropic gelation were characterized by SEM and was found to in the range of 200 nm.The mechanism by which drug is being released is non-Fickian(anomalous) solute diffusion mechanism. It is evident from the result that initial burst release was retarded or delayed due to adsorption of coating material. The in vivo biodistribution study results showed that the nanoparticles were having better distribution of drug compared to free drug in different organs like spleen, lungs, kidney etc.
Downloads
Metrics
Keywords:
Cytarabine, Deamination, Chitosan, Nanoparticles
Downloads
Published
How to Cite
Issue
Section
References
Alonso.M.J, Campos.A.M.D, Sancheg.A, Chitosan nanoparticles a new vehicle for the improvement of the delivery of durgs to the occular surface. Application to cyclosporine A.Int. J. Pharms. 229: 159-168 (2001).
Alonso.M.J, Fresneau.M.P, Marazuel.A, Fabra.A, James.K.A, Chitosan nanoparticles as delivery systems for doxorubicin. J.Controlld M.L. 73: 255-267 (2001).
Ana Grenha, Seijo.B, Lopez.C.R, Microencapsulated chitosan nanoparticles for lung protein delivery. Eur.J. Pharm Sci. 25: 427-437 (2005).
Ana Vila, Sanchez.A, Jsabel.k, Kisse.T, Jato.J.L.V, Alonso.M.J, Low moleculer weight chitosan nanoparticles as new carriers for nasal vaccire delivery in mice. Eur.J.Pharm and Biopharm. 57: 123-131 (2003).
Ana.A.K, Stevens.W.K, Lopez.C.R, Ionotropic cross linked chitosan microspheres for controlled release of ampicillin, 312: 16-173 (2006).
Blanco.M.D, Trigo.R.M, Teijon.C, Gomez.C, Teijion.J.M, Slow release of ara-c from poly (2-hydroxy ethyl methacrylate ) and poly(2-hydroxyethyl methacrylate-co-N-vinyl pyrolidone)hydrogels implanted subcutaneously in the back of rats. Biomaterials.19: 861-869 (1998).
Cho.Y.W, Park.J.S, Han.T.H, Lee.K.Y, Han.S.S, Hwang.J.J, Moon.D.H, Kim.S.Y, N.acetyl histidine-conjugated glycol chitosan self-assembled nanoparticles for intracytoplasmic delivery of drugs: Endocytosis, exocytosis and drug release,j.control.rel. 115: 37-45 (2006).
Colona.C,Conti.B,Perugini.P,Pavanatto.F,Modena.T,Dorat.R,Iadarola.D,Genta.I,Exvivo evaluation of prolidse loaded chitosan nanoparticles for the enzymereplacement therapy. Eur.J.Pharm and Biopharm. 70: 58-65 (2008).
Dadashazadeh.S, Derakhashandeh.K, Erfan.M.,. Encapsulation of 9-nitro-camphothecin, a ovel anticancer durg , in biodegradable nasnoparticles: Factorial desighn, characterization and release Kinetics. Eur J. Pharm and Biopharm. 66: 34-41 (2007).
Dass.C.R, Ta.H.T, Dunsta.D.E, Inject able chitosan hydrogel for localized cancer therapy, J. Control Rel. 126: 205-216 (2008).
Degobert.G, Abdel wahed.W, Stainmesse.S, Fessi.H, Freeze-drying of nanoparties: Formulation, process and storage conditions. Adv. Drug Delivery Reviews. 58: 1688-1713 (2006).
Dong-won Lee, Powers.K, Bane.R, Physicochemical properties and blood compatibility of acylated chitosan nanoparticles. Carbohydrates Polymers. 58: 371-377 (2004).
Du.Y, Wang.Q, Zhang.N, Hu.X, Yang.J, Chitosan/starch fibres and their properties for drug controlled release, Eur.J.Pharm and Bio pharm. 66: 398-404 (2007).
El-Shabouri.M.H, Positively charged nanoparticles for improving the oral bioavaivality of cyclosporine-A.Int. J. Pharms. 249: 101-108 (2002).
Fukumori.Y, Shikata.F, Tokumitsu.H, Ichikawa.H, Invitro cellular accumulation of gadolinium incorporated into chitosan nanosparticles desighned for neutrone capture therapy of cancer. Eur J. Pharm and Biopharm. 53: 57- 63 (2002).
Goepfuich.A, Breunig.M,. Baue.S, Polymers and nanoparticles: Intelligent tools for intrace forgetting. Eur.J. Pharm and Biopharm. 68: 112-128 2008).
Gomez.B.C, Duncan.R, Evaluation of the biological properties of soluble chitosan and chitosan microspheres, Int. J of pharm. 148: 231-240 (1997).
Hu.F.Q, Yan.H, Miao.J, Du.Y.Z, You.J, Jeng.S, Cellular uptake of soild-lipid nanoparticles and cytotoxicity of encapsulated paclitaxel in A549 cancer cells. Int.J. Pharm. 348: 137-195 (2008).
J.Siepmann, A.Streubel, N.A.Peppas. Understanding and predicting drug delivery from hydrophilic matrix tablets using the “sequential layer”model. PharmRes.19: 306- 314 (2002)
Kim.K, Kim.J.H ,Kim.Y.S, Park.K, Lee.S, Nam.H.Y, Min.K.H, Jo.H.G, Park.J.H, Choi.K, Jeong.S.Y, Park.R.W, Kim.I.S, Kwon.I.C,. Antitumor efficacy of cisplatin-loaded glycol chitosan nanoparticles in tumor- bearing mice. J. Control. Release. 127: 41-49 (2008).
Kim.Y.H, Hwang.H.Y, Kim.I, .Kwon.I.C,. Tumor targetability and antitumor effect of docetaxel loaded hydrophobically modified glycol chitosan nanoparticles. J. Control. Rel. 74: 317-323 (2008).
Li.B, Lin.J.M ,Rimme.E, VanRoey.M, Joss.K, Enhancement of the antitumor efficacy of GM-CSF-secreting tumor cell immunotherapy in preclinical models by cytosine arabinoside. Exp. Hematology. 36: 319-328 (2008).
Lifeng Qi, Xu.Z, Invivo antitumar activity of chitosan nanoparticles. Bioorganic and Med. Chemistry Letters.16: 4243-4245 (2006).
Lifeng Qi,.Xu.X, Jiang.X, Li.Y, Yang.M, Cytotoxic activities of chitosan nanoparticles and copper-loaded nanoparticles, Bioorganic and Med. Chem. let. 15: 1397-1399 (2005).
Maitra.A, Banarje.T, Mitra.S, Sing.A.K, Sharma.R.K, Preparation, characterization and biodistribution of ultrafine chitosan nanoparticles. Int. J. Pharms. 243: 93-105 (2002).
Maitra.A.N, Mitra.S, Gaur.U, Ghosh.P.C,. Tumor Targeted delivery of encapsulated dextran-doxorubicin conjugate using chitosan nanoparticles as carriers. J. Control. Release. 74: 317-323 (2001).
Maribel Teixeira, Alonso.M.J, Pinto.M.M.M, Bardosa.C.R, Development and characterization of PLGA nanspheres and nanocapsules containing Xanthone and 3-methoxy xanthone.Eur.J.Pharm and Biopharm. 59: 491-500 (2004).
Muller.B.W, Songrit.Y.B, Mitrevej.A, Chitosan durg binding by ionic reaction . Eur. J. Pharm and Biopharm. 62: 267-284 (2006).
Onshi.H, Unii.R.K, Machida.Y, Preparation and antitumor characteristics of PLA (PEG-PPG-PEG) nanoparticles loaded with campothecin,Eur.J.Pharm and Biopharm. 67: 9-17 (2007).
Patrick couvrier, Brigger.I, Duberne.C, Nanoparticles in cancer therapy and diagnosis, Adv. Drug Del Rev. 54: 631-651(2002).
Plunkett.W, Gandhi.V, Nucleoside analogs: Cellular pharmacology, mechanism of action. Nucleoside analogs in cancer therapy books. google.com. (1997).
Seijo.B, Grenha.A, Lopez.C.R, Carvallo.E, Microsphers containing lipid/ chitotan nanoparticles complxes for pulmonary delivery of therapeutic proteins. Eur J. Pharm and Biopharm. 69: 83-93 (2008).
Serpe.L, Catalano.M, Cavalli.R, Ugazio.E, Basco.O, Canaparo.R, Munton.E, Friaria.R, Grasco.M.R, Eandi.M, Zara.G.P, Cytotoxicity of anticancer drugs incorporated in solid lipid nanoparticles on HT-29 colorectal canter cell line. Eur.J. Pharm and Biopharm. 58: 673-680 (2009).
Sicvio Garattini, Pharmacokinetics in cancer cthemotherapy. Eur.J. Cancer. 43: 271-282 (2007).
Teijon.J.M, Gomez.C, Blanco.M.D, Bernardo.M.V, Olmo.R, Muniz.E.,. Cytarabine release from comatrices of albumin microspheres in a poly (lactide-co-glycolide) flim: invitro and invivo studies. Eur.J. Pharm and Biopharm. 57: 225-223 (2004).
Ugo Bilati, Allemann.E, Doelkar.E, Development of a nanoprecipitation method intended for the entrapment of hydrophilic drugs into nanoparticles Eur.J.Pharm Sci. 246: 7-75 (2004).
Xiong Wei Li, Lee.D.K.L, Chan.A.S.C, A.Oya. Alpar, Sustained expression in mammalian cells with DNA complexed with chitosan nanoparticles. Biochemica Et. Biophysica Acta. 1630: 7-18 (2003).
Yan Pan, Li.Y, Zhao.H.Y, Zheng.J.M, Xu.H, Wei.G, Song.J, Fu-de cui, Bioadhesive polysaccharide in protein delivery system: chitosan nanoparticles improve the intestinal absorbtion of insulin invivo. Int. J. Pharm. 249: 139-147 (2002).
Yan Wu, Yang.W, Wang.C ,Hu.J,Fu.S, Chitosan nanoparticles as a novel delivery system for ammonium glycyrrizinate. Int. J.Pharm. 295: 235-245 (2005).
Yang.W, Zheng.Y, Wang.C, Hu.J, Fu.S, Dong.L, Wu.L, Shen.X, nanoparticles based on the complex of chitosoan and polyaspartic acid sodium salt: Preparation, characterization and the use of 5-flurouracil delivery. Eur J. Pharm and Biopharm. 67: 621-631 (2007).
Yesim Aktas, Andrieux.K, Alonso.M.J, Calvo.P, Gurso.R.N, Couvreu.Pr, Capan.Y, Perparation and in vitro evaluation of chitosan nanoparticles containing a caspase inhibitor.Int. J.Pharm. 298: 378-383 (2005).
Zengshuan Ma, Lin.T.M, Lime.L.Y, Pharmacological activity of peroral chitosan-insulin nanoparticles in diabetics. Int.J.Pharm. 293: 271-280 (2005).
